Corneal Neovascularization and Ocular Irritancy Responses in Dogs Following Topical Ocular Administration of an EP4-Prostaglandin E2 Agonist

Toxicologic Pathology

Volumn 37, Issue 7, 2009, Pages 911-920

  Aguirre, Shirley A ^a   Huang, Wenhu ^a   Prasanna, Ganesh ^a   Jessen, Bart ^a  

^a PFIZER INC   (United States)

Author keywords

cornea; EP4 receptor agonist; neovascularization; prostaglandin E2

Indexed keywords

BLOOD CLOTTING FACTOR 8; PF 04475270; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMICROSCOPY; CELL DEATH; CELL INFILTRATION; CHEMOSIS; CILIARY BODY; CONJUNCTIVAL HYPEREMIA; CONTROLLED STUDY; CORNEA CELL; CORNEA EDEMA; CORNEA NEOVASCULARIZATION; DOG; EYE; EYE DISCHARGE; EYE IRRITATION; FEMALE; HISTOLOGY; HISTOPATHOLOGY; INFLAMMATORY CELL; INTRAOCULAR PRESSURE; IRIS; MALE; MIOSIS; NEUTROPHIL; NONHUMAN; OPHTHALMOLOGY; PRIORITY JOURNAL; SLIT LAMP; TREATMENT DURATION;

ADMINISTRATION, TOPICAL; ANIMALS; CORNEA; CORNEAL NEOVASCULARIZATION; DOGS; DRUG COMBINATIONS; EYE; FACTOR VIII; INTRAOCULAR PRESSURE; PYRROLIDINONES; RECEPTORS, PROSTAGLANDIN E; THIOPHENES; TOXICITY TESTS; VON WILLEBRAND FACTOR;

CANIS FAMILIARIS;

EID: 74949120198     PISSN: 01926233     EISSN: None     Source Type: Journal    
DOI: 10.1177/0192623309351724     Document Type: Article

References (21)

1. Bito LZ A new approach to the medical management of glaucoma, from the bench to the clinic, and beyond: The proctor lecture Invest Ophthalmol Vis Sci 2001 42 1126 33
2. Bito LZ Draga A Blanco J Camras CB Long-term maintenance of reduced intraocular pressure by daily or twice daily topical application of prostaglandins to cat or rhesus monkey eyes Invest Ophthalmol Vis Sci 1983 24 312 19
3. Breyer RM Bagdassarian CK Myers SA Breyer MD Prostanoid receptors: Subtypes and signaling Ann Rev Pharmacol Toxicol 2001 41 661 90
4. Chen J Dinh T Woodward DF Holland JM Yuan YD Lin TH Wheeler LA Bimatoprost: Mechanism of ocular surface hyperemia associated with topical therapy Cardiovas Drug Rev 2005 23 231 46
5. Hellberg MR McLaughlin MA Sharif NA DeSantis L Dean TR Kyba EP Bishop JE Klimko PG Zinke PW Selliah RD Barnes G DeFaller J Kothe A Landry T Sullivan EK Andrew R Davis AA Silver L Bergamini MVW Robertson S Weiner AL Sallee VL Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonist Surv Ophthalmol 2002 47 S13 S33
6. Honrubia F Garcia SJ Polo V Martinez d1CJM Soto J Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: A meta-analysis of randomised clinical trials Br J Ophthalmol 2009 93 316 21
7. Inoue H Takamori M Shimoyama Y Ishibashi H Yamamoto S Koshihara Y Regulation by PGE(2) of the production of interleukin-6, macrophage colony stimulating factor, and vascular endothelial growth factor in human synovial fibroblasts Br J Pharmacol 2002 136 287 95
8. Kuwano T Nakao S Yamamoto H Tsuneyoshi M Yamamoto T Kuwano M Ono M Cyclooxygenase 2 is a key enzyme for inflammatory cytokine-induced angiogenesis FASEB J 2004 18 300 10
9. Maggs DJ Miller PE Ofri R Slatter’s Fundamentals of Veterinary Ophthalomology 2008 St. Louis, MO Saunders Elsevier
10. Miranda OC Bito LZ The putative and demonstrated miotic effects of prostaglandins in mammals Prog Clin Biol Res 1989 312 171 95
11. Narumiya S Sugimoto Y Ushikubi F Prostanoid receptors: Structures, properties, and functions Physiol Rev 1999 79 1193 226
12. Nilsson SFE Drecoll E Lutjen DE Toris CB Krauss AHP Kharlamb A Nieves A Guerra T Woodward DF The prostanoid EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey Invest Ophthal Vis Sci 2006 47 4042 49
13. Pavlovic S Du B Sakamoto K Khan KMF Natarajan C Breyer RM Dannenberg AJ Falcone DJ Targeting prostaglandin E-2 receptors as an alternative strategy to block cyclooxygenase-2-dependent extracellular matrix-induced matrix metalloproteinase-9 expression by macrophages J Biol Chem 2006 281 3321 28
14. Prasanna G Fortner J Xiang C Zhang E Carreiro S Anderson S Sartnurak S Wu G Gukasyan HJ Niesman M Nair S Rui E Lafontaine J Almaden CD Wells P Krauss A Ocular pharmacokinetics and hypotensive activity of PF-04475270, an EP4 prostaglandin agonist in preclinical models Exp Eye Research 2009 89 608 17
15. Rao R Redha R Macias-Perez I Su Y Hao C Zent R Breyer MD Pozzi A Prostaglandin E2-EP4 receptor promotes endothelial cell migration via ERK activation and angiogenesis in vivo J Biol Chem 2007 282 16959 68
16. Stern FA Bito LZ Comparison of the hypotensive and other ocular effects of prostaglandins E2 and F2 alpha on cat and rhesus monkey eyes Invest Ophthal Vis Sci 1982 22 588 98
17. Stjernschantz J Selén G Astin M Resul B Microvascular effects of selective prostaglandin analogues in the eye with special reference to latanoprost and glaucoma treatment Prog Retin Eye Res 2000 19 459 96
18. Sugimoto Y Narumiya S Prostaglandin E receptors J Biol Chem 2007 282 11613 617
19. Toris CB Camras CB Yablonski ME Brubaker RF Effects of exogenous prostaglandins on aqueous humor dynamics and blood-aqueous barrier function Surv Ophthalmol 1997 41 S69 75
20. Woodward DF Nilsson SFE Toris CB Kharlamb AB Nieves AL Krauss AH Prostanoid EP4 receptor stimulation produces ocular hypotension by a mechanism that does not appear to involve uveoscleral outflow Invest Ophthal Vis Sci 2009 50 3320 28
21. Woodward DF Phelps RL Krauss AHP Weber A Short B Chen J Liang Y Wheeler LA Bimatoprost: A novel antiglaucoma agent Cardiovasc Drug Rev 2004 22 103 20